CIM Q1 2026 Earnings Modest EPS Beat as Interest Rate Dynamics Shape Performance Halozyme Therapeutics Inc HALO Q1 2026 Earnings EPS Surpasses Estimates Despite Flat Revenue Disclosure BLFY Q3 2025 Earnings NarrowerthanExpected Loss Despite EPS Miss PKX Q4 2025 Earnings Massive EPS Miss Exceeds Negative Surprise Amidst Challenging Conditions XCUR Q2 2022 Earnings EPS Miss Widens as PreRevenue Biotech Shares Edge Higher IFS Q1 2026 Earnings Earnings Beat Estimates as EPS Surprises by 1095